3 weeks ago
Wockhardt Returns to Profit in Q1, Revenue Up 26%
Wockhardt is a company that makes medicines.
It is based in Mumbai.
The company told everyone how much money it made in the three months ending in June 2026.
During that time, it earned a profit of 107 crore rupees.
A crore is a very big number, equal to ten million.
One year earlier, the company lost 108 crore rupees.
Now it is making money again.
The company also sold more medicines, earning 26 percent more money than before.
If you owned one share of the company, it earned about 6.55 rupees for you.
The company's leaders checked these numbers and approved them on August 10, 2026.
Wockhardt Limited reported a consolidated net profit of Rs 107 crore for the quarter ended 30 June 2026, versus a loss of Rs 108 crore in the year-ago quarter.
Consolidated revenue from operations rose 26% year-on-year to Rs 929 crore, up from Rs 738 crore in the quarter ended 30 June 2025.
Total consolidated income stood at Rs 960 crore, up from Rs 758 crore a year earlier but down from Rs 1,010 crore in the preceding quarter ended 31 March 2026.
Basic and diluted earnings per share improved to Rs 6.55 from negative Rs 5.53 in the corresponding quarter of the previous year.
The results were reviewed by the Audit Committee and approved by the Board of Directors on 10 August 2026, with a limited review by statutory auditors.
- Who
- Wockhardt Limited, a Mumbai-based pharmaceutical company
- What
- Reported a consolidated net profit of Rs 107 crore and a 26% year-on-year rise in revenue from operations for the quarter ended 30 June 2026.
- Where
- Mumbai
- When
- Quarter ended 30 June 2026; results approved by the board on 10 August 2026
- Why
- The company returned to profitability after a loss of Rs 108 crore in the same quarter last year, driven by higher consolidated revenue.
Key facts
- Company
- Wockhardt Limited
- Quarter
- Quarter ended 30 June 2026
- Net Profit
- Rs 107 crore (vs loss of Rs 108 crore year ago)
- Revenue from Operations
- Rs 929 crore, up 26% year-on-year
- Total Income
- Rs 960 crore
- Total Expenses
- Rs 844 crore
- Earnings Per Share
- Basic and diluted Rs 6.55
- Business Segment
- Pharmaceuticals
Sources
Related news
Jubilant FoodWorks Profit Rises 6%, Revenue Jumps 14% in Q1
P&G Health Q1 Net Profit Rises 45% to ₹96.15 Crore
Aurobindo Pharma Q1 profit up 25%, record ₹9,150 crore revenue
Emcure Pharma Q1 Net Profit Up 36% to ₹292.49 Crore
Maharashtra Land Bank Aims to Speed Infrastructure Projects
India Replaces Sri Lanka as 2027 Women’s Champions Trophy Host
BCCI Review To Assess Rohit Sharma’s World Cup Future
Tukaram Mundhe Warns Indians About Food Safety Risks
India to Host Inaugural Women’s Champions Trophy in 2027
